BioSight
Companies
Travere Therapeutics, Inc. logo

TVTX

NASDAQSAN DIEGO, CA
Travere Therapeutics, Inc.

Travere Therapeutics develops medications for rare kidney and metabolic diseases. The company's marketed product is FILSPARI (sparsentan) for Immunoglobulin A nephropathy, and it is advancing pegtibatinase in Phase 3 trials for classical homocystinuria, with a supplemental application under FDA review for sparsentan in focal segmental glomerulosclerosis.

Price history not yet available for TVTX.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar